Rigel Pharmaceuticals, Inc. (RIGL) Stock Price & Analysis
Rigel Pharmaceuticals, Inc. (RIGL) closed at USD 50.74 on Wednesday, October 28, 2026, up 0.38% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 50.55; the Oct 28, 2026 session ranged USD 50.06–51.32 on volume of 226,309 shares. Market capitalization is $947.82M, with a 52-week range of USD 24.95–52.24 (NMS). Source: Nexqual, retrieved October 29, 2026 at 06:04 UTC.
Also available as compact Markdown for AI agents: nexqual.com/RIGL.md
Key facts (RIGL)
- Last four reported quarters (through Jun 30, 2026): revenue $277M, net income $322M (116.3% margin) (SEC filings).
- Valuation: P/E 2.9x (avg 9.6x at the last 2 fiscal year-ends).
- Insider open-market sales, last ~7 months: 2 Form 4 filings, $160K; 0 not under a Rule 10b5-1 plan ($0K); 0 by opportunistic insiders, 0 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
- Analysts: Buy (mean 2.40 on a 1–5 scale) (5 analysts), mean target USD 63 (range 43–85).
- Total return with dividends: 1Y +72.6% vs S&P 500 +13.6%; 5Y +51.0% vs S&P 500 +79.8%.
- Next earnings: 2026-11-03, EPS estimate USD 0.96, revenue estimate $80.1M.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (RIGL)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $149M | $120M | $117M | $179M | $294M | $277M |
| Gross profit | $148M | $118M | $110M | $161M | $275M | — |
| Operating income | -$12.5M | -$55.5M | -$20.5M | $24.2M | $125M | $87.0M |
| Net income | -$17.9M | -$58.6M | -$25.1M | $17.5M | $367M | $322M |
| EPS (diluted) | -$1.10 | -$3.44 | -$1.44 | $0.99 | $19.48 | — |
| Free cash flow | $5.3M | -$74.2M | — | — | — | — |
| Gross margin | 99.3% | 98.5% | 93.9% | 89.6% | 93.3% | — |
| Operating margin | -8.4% | -46.2% | -17.5% | 13.5% | 42.6% | 31.5% |
| Net margin | -12.0% | -48.7% | -21.5% | 9.8% | 124.7% | 116.3% |
| Revenue growth | +37.4% | -19.4% | -2.8% | +53.4% | +64.1% | — |
| Cash + short-term investments | $125M | $58.2M | $56.9M | $77.3M | $155M | — |
| Total debt | $20.0M | $40.0M | $60.0M | $60.0M | $52.5M | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (RIGL)
P/E 2.9x · P/S 3.4x · P/B 2.2x · Earnings yield 33.96%
P/E at fiscal year-ends: Dec 2025 2.2x, Dec 2024 17.0x.
Insider sales (SEC Form 4, open-market, last ~7 months) (RIGL)
2 of 2 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.
| Trade date | Insider | Role | Shares | Value | % of holdings sold | 10b5-1 plan | Insider type |
|---|---|---|---|---|---|---|---|
| 2026-06-22 | Ali-Jackson Kamil | Director | 2,500 | $88K | 19.8% | Yes (adopted November 7, 2025) | Too little history (no open-market trades in 2023–2025) |
| 2026-05-26 | Ali-Jackson Kamil | Director | 2,500 | $73K | 16.5% | Yes (adopted November 7, 2025) | Too little history (no open-market trades in 2023–2025) |
% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.
Analysts (RIGL)
Consensus Buy (mean 2.40 on a 1–5 scale), 5 analysts; mean target USD 63 (low 43, high 85).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-19 | HC Wainwright & Co. | Reiterated | Buy | $85 |
| 2026-08-17 | Piper Sandler | Target raised | Neutral | $40 → $49 |
| 2026-08-14 | HC Wainwright & Co. | Target raised | Buy | $57 → $85 |
Total return (dividends reinvested) (RIGL)
| 1Y (from 2025-10-29) | 5Y (from 2021-10-25) | |
|---|---|---|
| Total return | +72.6% | +51.0% |
| S&P 500 (SPY) | +13.6% | +79.8% |
| Per year | +72.9% | +8.6% |
| Volatility (annualized) | 60.9% | 89.4% |
| Max drawdown | -50.1% (Nov 2025→Mar 2026) | -80.6% (Mar 2022→Jun 2022) |
RIGL earnings history and stock reaction
| Results filed | Quarter | EPS | Consensus | Surprise | Stock reaction |
|---|---|---|---|---|---|
| — | Quarter ended Jun 30, 2026 | $0.88 | −$0.08 | Beat +$0.96 | — |
| — | Quarter ended Mar 31, 2026 | $0.44 | $0.87 | Miss −49.4% | — |
| — | Quarter ended Dec 31, 2025 | $1.12 | $1.20 | Miss −6.7% | — |
| — | Quarter ended Sep 30, 2025 | $1.46 | $0.94 | Beat +55.3% | — |
EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).
RIGL recent SEC filings (last 120 days)
| Filed | Form | What it says |
|---|---|---|
| Aug 14, 2026 | Schedule 13G/A | Armistice Capital, LLC, Steven Boyd: 8.9% of shares, passive 5%+ holder (amended) |
| Aug 13, 2026 | Schedule 13G/A | Soleus Capital Master Fund, L.P., Soleus Capital, LLC: 9.9% of shares, passive 5%+ holder (amended) |
| Aug 4, 2026 | 8-K | Quarterly results |
| Aug 4, 2026 | 10-Q | Quarterly report · period ended Jun 30, 2026 |
| Jul 1, 2026 | 8-K | Director or executive officer change, or pay arrangement “On July 1, 2026, Rigel Pharmaceuticals, Inc. (the "Company") announced that Alison L. Hannah, M.D. was appointed Executive Vice President and Chief Medical Officer of the Company. In connection with her appointment, Dr. Hannah resigned from the Company's Board of Directors (the "Board"), effective July 1, 2026. Dr. Hannah had served as a member of the Board since May 2021. Since 2000, Dr. Hannah has served as a consultant to the pharmaceutical and biotechnology industry, directing the development of…” |
Source: SEC EDGAR. Quotes are the opening words of each item as filed; each form links to the filing. Insider Form 4 filings are listed in the insider sections.
RIGL revenue by product line (quarter ended Jun 30, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| Gross product sales | $88.5M | 112.4% | +11.0% |
| Product sales, net | $67.0M | 85.1% | +13.7% |
| Contract revenues from collaborations and other | $11.7M | 14.9% | -72.7% |
| Delivery of drug supplies, royalties and others | $7.7M | 9.8% | +179.0% |
| Development Milestones | $4.0M | 5.1% | — |
| Total revenue | $78.7M | 100% | — |
As tagged by the company in its SEC 10-Q / 10-K filings (XBRL).
RIGL suppliers, customers and competitors (named in its 10-K)
| Relationship | Company | Sentence in the filing |
|---|---|---|
| Partner | Eli Lilly (LLY) | “We also have a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor program in clinical development that is being led by our partner Eli Lilly and Company (Lilly).” |
| Partner | Jefferies | “We have an Open Market Sale Agreement with Jefferies LLC (Jefferies) entered on August 4, 2020, and amended and restated on August 2, 2024, pursuant to which, we may sell from time to time, through Jefferies, shares of our common stock in sales deemed to be "at-the-market offerings" as defined in Rule 415 under the Securities Act, subject to conditions specified in the Open Market Sale Agreement, including maintai…” |
| Partner | Healthpeak OP | “We have a contractual commitment related to our lease agreement with 611 Gateway, now with Healthpeak following the completion of the property acquisition from 611 Gateway in January 2026, which lease will expire in July 2027.” |
| Partner | Atara Biotherapeutics, Inc. (ATRA) | “In February 2025, we entered into a lease agreement with 611 Gateway, now with Healthpeak following the completion of the property acquisition from 611 Gateway in January 2026, to lease the same office space, which lease term commenced following the expiration of the sublease with Atara and will expire in July 2027.” |
Quoted from the company's 10-K filed Mar 3, 2026.
RIGL customer concentration
In the period ended Jun 30, 2026, 3 direct customers each accounted for at least 10% (46%, 21%, 0%) of revenue, per the company's 10-Q filed Aug 4, 2026. The company does not name them.
RIGL company outlook (results filed Aug 4, 2026)
- “Outlook: Total revenues of approximately $285 to $295 million, which includes net product sales, excluding VEPPANU, of $255 to $265 million and contract revenues from collaborations of approximately $30 million • Conference call and webcast scheduled today at 4:30 p.m.”
Quoted word-for-word from the SEC 8-K results press release.
RIGL analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $0.96 | $1.22 | -20.8% | $80.1M | 4 |
| Next quarter (ends Dec 2026) | $1.04 | $1.23 | -15.7% | $88.1M | 4 |
| Current fiscal year (ends Dec 2026) | $3.54 | $2.89 | +22.5% | $305.7M | 4 |
| Next fiscal year (ends Dec 2027) | $4.94 | $4.83 | +2.2% | $372.8M | 4 |
Key Statistics (as of October 29, 2026 at 06:04 UTC)
| Price | USD 50.74 |
|---|---|
| Change | ▲ 0.38% (up) |
| Previous Close | USD 50.55 |
| Open | USD 50.26 |
| Day Range | USD 50.06 – 51.32 |
| 52-Week Range | USD 24.95 – 52.24 |
| Volume | 226,309 shares |
| Market Cap | $947.82M |
| Exchange | NMS |
Technical Analysis (RIGL)
Nexqual's technical model rates RIGL "BUY" based on 5 bullish and 2 bearish signals across 127 daily candles, as of October 29, 2026 at 06:04 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 62.08 (neutral) |
| vs SMA50 | Above (USD 47.48) |
| MACD | 0.8 (positive) |
Analyst Ratings (RIGL)
Wall Street analysts rate RIGL "Buy" based on 5 analysts, with a mean price target of USD 63 (range USD 43–85), per Nexqual as of October 29, 2026 at 06:04 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 5 |
| Mean Target | USD 63 |
| High Target | USD 85 |
| Low Target | USD 43 |
| Buy / Hold / Sell | 3 / 2 / 0 |
Earnings (RIGL)
| Next Earnings Date | 2026-11-03 |
|---|---|
| EPS Estimate | USD 0.96 |
| Revenue Estimate | $80.10M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 0.88 vs est -0.08 ▲ beat |
| 2026-03-31 | USD 0.44 vs est 0.87 ▼ miss |
| 2025-12-31 | USD 1.12 vs est 1.2 ▼ miss |
| 2025-09-30 | USD 1.46 vs est 0.94 ▲ beat |
Source: Nexqual, October 29, 2026 at 06:04 UTC.
Financials & Fundamentals (RIGL)
| Total Revenue | $276.78M |
|---|---|
| Revenue Growth (latest quarter, YoY) | -22.60% |
| Gross Margin | +75.61% |
| Operating Margin | +29.95% |
| Profit Margin | +116.30% |
| ROE | +126.90% |
| Debt / Equity | 0.09 |
| Current Ratio | 1.94 |
| Total Cash | $95.33M |
| Total Debt | $39.95M |
Source: Nexqual, October 29, 2026 at 06:04 UTC.
Financial Health Score (RIGL)
Nexqual rates Rigel Pharmaceuticals, Inc.'s overall financial health "Strong" across five dimensions, as of October 29, 2026 at 06:04 UTC.
| Growth | Strong — Revenue +64% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 91%, operating 31% (last 4 quarters to Jun 2026, SEC) |
| Balance Sheet | Strong — $147M cash and investments vs $45M debt (Mar 2026, SEC), net cash |
| Cash Flow | Solid — Operating cash flow $76M (FY ended Dec 2025, 10-K) |
| Efficiency | Strong — ROE 76%, ROA 61.8% (last 4 quarters, SEC) |
Ownership (RIGL)
| Insider Ownership | +3.35% |
|---|---|
| Institutional Ownership | +92.56% |
| Shares Outstanding | 18.68M |
| Float | 14.84M |
| Short % of Float | +15.02% |
Source: Nexqual, October 29, 2026 at 06:04 UTC.
Leadership (RIGL)
Rigel Pharmaceuticals, Inc. is led by Raul R. Rodriguez, President, CEO & Director, per Nexqual as of October 29, 2026 at 06:04 UTC.
| President, CEO & Director | Raul R. Rodriguez |
|---|---|
| Executive VP & CFO | Dean L. Schorno |
| Vice President of Marketing | Tarek Sallam |
Major Backers & Investors (RIGL)
Notable institutional backers of Rigel Pharmaceuticals, Inc. include Soleus Capital Management, L.P., Armistice Capital, LLC, American Century Companies Inc, according to Nexqual as of October 29, 2026 at 06:04 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Soleus Capital Management, L.P. | 9.96% |
| Armistice Capital, LLC | 9.04% |
| American Century Companies Inc | 4.01% |
| LSV Asset Management | 3.9% |
| Acadian Asset Management. LLC | 3.2% |
| Shaw D.E. & Co., Inc. | 2.93% |
| Assenagon Asset Management S.A. | 2.9% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 10.48% |
| State Street | 5.62% |
| Vanguard Group | 4.24% |
Source: Nexqual, October 29, 2026 at 06:04 UTC.
From Rigel Pharmaceuticals, Inc.'s Latest SEC 10-K Filing (filed 2026-03-03)
Key Strengths & Strategy (as disclosed to the SEC)
- The litigation resulted from submission by Annora of an Abbreviated New Drug Application (ANDA) to the FDA seeking approval to market a generic version of TAVALISSE in the US.
- Grifols has launched TAVLESSE in the UK and certain countries in EU including Germany, France, Italy and Spain, and continues a phased rollout across the rest of EU.
Partnerships
- In February 2021, we entered global exclusive license and strategic collaboration with Lilly to develop and commercialize ocadusertib (previously R552), an investigational, potent and selective RIPK1 inhibitor, for the treatment of non-central nervous system (non-CNS) diseases, and additional RIPK1 inhibitors for the treatment of central nervous system (CNS) diseases.
- We have a commercialization license agreement with Grifols for exclusive rights to commercialize fostamatinib for human diseases, and non-exclusive rights to develop, fostamatinib in their territory.
Legal & Regulatory Risks (Item 1A, quoted)
- Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors, which may adversely affect our future profitability.
- We cannot predict the likelihood, nature, or extent of health reform initiatives that may arise from future legislation or administrative action.
- Regulatory approval for any approved product is limited by the FDA, the EC and other regulators to those specific indications and conditions for which clinical safety and efficacy have been demonstrated, and we may incur significant liability if it is determined that we are promoting the "off-label" use of our products or any of our future product candidates if approved.
- We have conducted in the past and are currently conducting or may conduct in the future clinical trials in the US and outside the US.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ORKA | Oruka Therapeutics, Inc. | USD 95.97 | ▲ 0.17% |
| LGND | Ligand Pharmaceuticals Incorpor | USD 318.78 | ▲ 2.26% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.81 | ▲ 1.58% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 44.9 | ▲ 2.14% |
| AXSM | Axsome Therapeutics, Inc. | USD 143.51 | ▲ 0.92% |
| ABVX | Abivax SA | USD 89.84 | ▲ 3.26% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 29, 2026 at 06:04 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt